Register for free to
view the full innovation profile.
Compounds from this series will lead to improved drugs and other treatments for infectious diseases such as malaria and a range of bacterial infections.
About
Description The fight against malaria, tuberculosis, and other infectious diseases is growing more difficult due to the emergence of drug resistant forms of these diseases. Recent studies have shown that bacterial and parasitic organisms, like those involved in malaria and tuberculosis, use a methylerythritol isoprenoid (MEP) biosynthetic pathway to produce isoprenoids. Isoprenoids found in living organisms are the basic building blocks of many essential substances and range in function from pigmentation, fragrances, vitamin production and precursors of sex hormones. Humans do not use the MEP pathway process; therefore any foreign pathogen in the human body that uses the MEP pathway can be targeted by recognizing enzymes (specifically IspF) associated with MEP. This invention is a series of synthetic compounds designed to inhibit the enzyme IspF present in the MEP pathway. Compounds from this series will lead to improved drugs and other treatments for infectious diseases such as malaria and a range of bacterial infections